LinkedIn facebook twitter youtube
News archive
Recent news


Myeloma is the disease with the highest number of approved drugs over the last 15 years. Actually, the prognosis of the disease has been tripled. As myeloma is a very heterogeneous disease, not all treatments are suitable for each patient. The challenge now is to choose the right treatment for each individual patient in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and reduce healthcare costs.

With the aim of providing an overview of personalised medicines in myeloma, Myeloma Patients Europe (MPE) will hold a webinar on Tuesday 25 June from 18:00 to 19:00 CET.

The webinar will be given by Dr Annemiek Broijl, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

The webinar will last around 60-minutes, including a 40-minute presentation by Dr Broijl followed by a 20-minute Q&A session.

Registration is free of charge. Please feel free to forward the registration link to colleagues who might be interested in attending the webinar.

Should you be unable to attend the webinar, please feel free to send your questions in advance to info@mpeurope.org and we will make sure they reach our speaker.

A recording of the webinar will be available shortly after the session.

We look forward to your participation!






Recent news

» Daratumumab approved for first line treatment in Israel

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy